Solving serotonin-dependent
diseases: novel TPH1 inhibitors
Our technology
Novel class of TPH1 inhibitors
Binding to the Trp (substrate) and BH4 (co-factor) binding pockets of TPH1 simultaneously.
Potent inhibition of 5-HT production in vitro and in vivo.
TRYPTO THERAPEUTICS is developing a set of novel, proprietary small molecules at TRL level 4 to treat serotonin-related diseases.
We have developed and patented a novel class of TPH inhibitors (TPHi) with nanomolar potency in vitro.
Our TPHi differ in their scaffold, binding mode, and potency from TPHi that are currently on the market or under clinical investigation.
The lead TPHi compound achieved readiness to transition from academic research towards a targeted pharmaceutical development.
Comprehensive data package:
Potency & selectivity in vitro
ADME / TOX in vitro
PK in vivo
PD in vivo
Safety and toxicity in vivo
Completed development milestones:
Suitable ADME / Tox
Oral PK profile
Reproduced Proof of Concept in PAH
CMC process established
Proof of Concept for CMC scalability
Strong IP protection
Target indications and pipelines focus
-
Main indication: Pulmonary Arterial Hypertension (PAH)
Increased serotonin levels in the periphery contribute to pulmonary vessel remodelling and aggravate the disease progression.
-
Secondary indication: Carcinoid Syndrome (CS)
Pathologically high serotonin levels produced by NET tumours with metastatic surroundings trigger gastrointestinal and cardiac symptoms in CS patients.
-
Explorative: Non-alcoholic steatohepatitis (NASH)
Peripheral serotonin regulates metabolism, but might also contribute to local inflammatory processes and fibrotic changes in the liver.
-
Explorative: Fibrotic and inflammatory diseases
Serotonin is pathogenetically relevant for different kinds of fibrotic diseases of the lungs, liver, skin and kidneys.